GlassScriptPhysician profile
Andrew Swenson
NPI 1174012934
$6,259.23
in general payments reported to CMS, 2019-2025
48 companies · $1,953 in 2025
The $1,953 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $425 · 2022: $1,275 · 2023: $1,189 · 2024: $1,417 · 2025: $1,953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,510 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,509.59 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,094.44 | 2021-2025 | Vraylar, Qulipta |
| Lilly USA, LLC | $542.95 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $458.54 | 2022-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $405.66 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $364.59 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $356.11 | 2022-2025 | Shingrix, Arexvy |
| Novo Nordisk INC | $304.59 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $280.99 | 2021-2025 | |
| Axsome Therapeutics, INC. | $241.92 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $226.92 | 2022-2025 | Rexulti, Abilify Maintena |
| Astellas Pharma US INC | $215.10 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $195.99 | 2021-2025 | Gardasil 9, M-M-R II, Vaxelis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.16 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $100.44 | 2022-2024 | |
| Dynavax Technologies Corporation | $94.68 | 2021-2025 | Heplisav-B |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Swenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.